- Polymer Chain Reaction (PCR)
- Next-generation sequencing
Respiratory Molecular Diagnostics Market is expected to grow at a compound annual growth rate (CAGR) of 7.1%. The rising prevalence of respiratory illnesses, particularly among the aging population, increased demand for advanced diagnostics with the integration of AI, data analysis, and technological advancements (imaging, molecular diagnostics, rapid tests) are fuelling the respiratory molecular diagnostics market. This growth is driven by the need for early detection, personalized treatment, and efficient response to outbreaks. Conversely, environmental pollution increases the patient pool, while the COVID-19 pandemic significantly boosted the market due to the need for accurate and rapid testing. Hospitals adopted stricter protocols to prevent cross-infection during the pandemic, leading to increased focus on respiratory diagnostics. However, the high cost of advanced technologies for diagnostics and the limited resources and awareness remain challenges and hurdles.
Respiratory Molecular Diagnostics Market Key Developments:
- In 2023, The Alinity m Resp-4-Plex assay, a one-step test approved by the FDA, detects and differentiates between SARS-CoV-2, influenza A/B, and respiratory syncytial virus.
- August 2, 2023, Becton, Dickinson and Company (BD) has received 510(k) clearance from the US Food and Drug Administration (FDA) for its single molecular diagnostic combination test, BD Respiratory Viral Panel (RVP) for BD MAX System.
Respiratory Molecular Diagnostics Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
7.1%
Largest Market
North America
Fastest Growing Market
Asia Pacific
Respiratory Molecular Diagnostics Market Dynamics
The respiratory molecular diagnostics market is experiencing significant growth driven by the integration of advanced technologies such as polymer chain reaction (PCR), the most widely used technology, which amplifies specific DNA or RNA sequences, allowing for the detection of pathogens even when present in low numbers, and Loop-mediated isothermal amplification (LAMP) is a relatively new and simpler technique compared to PCR, making it suitable for point-of-care applications, increased demand for rapid diagnostics after the COVID-19 pandemic, and raising awareness of respiratory diseases have fuelled the need for rapid and accurate testing and cost-effective diagnosis, and the challenges include high cost and limited awareness about advanced technologies for diagnostics can hinder the adoption of products.
North-America Got Significant Share of
Respiratory Molecular Diagnostics Market Regional Analysis
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Asia Pacific is the fastest-growing region, driven by rising healthcare spending, increased disease awareness, and government initiatives. North America is dominating the market with a well-established healthcare infrastructure, advanced technology adoption, and robust R&D funding, leads the pack. Europe follows closely, known for its mature market and focus on quality and innovation Latin America's market, though growing, remains fragmented due to diverse healthcare infrastructure and economic development across countries. Finally, while the Middle East & Africa has the lowest market share currently, significant growth is anticipated in the coming years due to increased healthcare investments and rising disease awareness
Latin America
Europe
Asia Pacific
Middle East
North America
Respiratory Molecular Diagnostics Market Segmentation
By Technology
By Disease Indicator
Virus
- Influenza
- RSV
- COVID 19
- Parainfluenza
- hMPV
- Rhinovirus
- Adenovirus
Bacteria
- Chlamydophila Pneumonia
- Mycoplasma pneumoniae
- Bordetella Pertussis/Parapertussis/Holmesii
- Legionella pneumoniae
By End User
- Hospitals
- Research Institutions
- Point Of Care Setting
Frequently Asked Questions
The respiratory molecular diagnostics market is expected to grow a compound annual growth rate (CAGR) of 7.1%.
Abbott Laboratories (US), Roche Diagnostics (Switzerland), Thermo Fisher Scientific (US), BD (Becton, Dickinson and Company) (US), Hologic, Inc. (US), Qiagen (Netherlands), and Seegene Inc. (South Korea)
Asia-Pacific is the fastest growing and North America is the dominant market in respiratory molecular diagnostics.
Key Features of the Reports
- The respiratory molecular diagnostics market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.
| 1.Executive Summary |
| 2.Global Respiratory Molecular Diagnostics Market Introduction |
| 2.1.Global Respiratory Molecular Diagnostics Market - Taxonomy |
| 2.2.Global Respiratory Molecular Diagnostics Market - Definitions |
| 2.2.1.Technology |
| 2.2.2.Disease Indicator |
| 2.2.3.End-user |
| 2.2.4.Region |
| 3.Global Respiratory Molecular Diagnostics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Respiratory Molecular Diagnostics Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Respiratory Molecular Diagnostics Market By Technology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Polymer Chain Reaction (PCR) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Next-generation sequencing |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Respiratory Molecular Diagnostics Market By Disease Indicator, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Virus |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Bacteria |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Respiratory Molecular Diagnostics Market By End-user, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Research Institutions |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Point Of Care Setting |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8.Global Respiratory Molecular Diagnostics Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Respiratory Molecular Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Technology Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Polymer Chain Reaction (PCR) |
| 9.1.2.Next-generation sequencing |
| 9.2. Disease Indicator Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Virus |
| 9.2.2.Bacteria |
| 9.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Research Institutions |
| 9.3.3.Point Of Care Setting |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Respiratory Molecular Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Polymer Chain Reaction (PCR) |
| 10.1.2.Next-generation sequencing |
| 10.2. Disease Indicator Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Virus |
| 10.2.2.Bacteria |
| 10.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Research Institutions |
| 10.3.3.Point Of Care Setting |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Respiratory Molecular Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Polymer Chain Reaction (PCR) |
| 11.1.2.Next-generation sequencing |
| 11.2. Disease Indicator Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Virus |
| 11.2.2.Bacteria |
| 11.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Research Institutions |
| 11.3.3.Point Of Care Setting |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Respiratory Molecular Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Polymer Chain Reaction (PCR) |
| 12.1.2.Next-generation sequencing |
| 12.2. Disease Indicator Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Virus |
| 12.2.2.Bacteria |
| 12.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Research Institutions |
| 12.3.3.Point Of Care Setting |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Respiratory Molecular Diagnostics Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Polymer Chain Reaction (PCR) |
| 13.1.2.Next-generation sequencing |
| 13.2. Disease Indicator Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Virus |
| 13.2.2.Bacteria |
| 13.3. End-user Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Research Institutions |
| 13.3.3.Point Of Care Setting |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Koninklijke Philips N.V. (Netherlands) |
| 14.2.2.BD (US), |
| 14.2.3.Abbott (US) |
| 14.2.4.Thermo Fisher Scientific Inc. (US) |
| 14.2.5.GE HealthCare (US) |
| 14.2.6.Bio-Rad Laboratories, Inc. (US) |
| 14.2.7.BioMérieux (France) |
| 14.2.8.Revvity, Inc. (US) |
| 14.2.9.Seegene Inc. (South Korea), |
| 14.2.10.Nihon Kohden Corporation (Japan) |
| 14.2.11.Vitalograph (UK) |
| 14.2.12.SDI Diagnostics (US) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Koninklijke Philips N.V. (Netherlands)
- BD (US),
- Abbott (US)
- Thermo Fisher Scientific Inc. (US)
- GE HealthCare (US)
- Bio-Rad Laboratories, Inc. (US)
- BioMérieux (France)
- Revvity, Inc. (US)
- Seegene Inc. (South Korea),
- Nihon Kohden Corporation (Japan)
- Vitalograph (UK)
- SDI Diagnostics (US)
- ResMed Inc. (US)
- Siemens Healthcare GmbH (Germany)
- Cosmed (Italy), Hologic, Inc. (US)
- Qiagen (Netherlands),
- Vyaire (US)
- Visby Medical, Inc (US)
- Briota Technologies Private Limited (India)
- Bird Healthcare (Australia)
- Löwenstein Medical Technology (Germany)
- ProAxsis (Northern Ireland),
- Compumedics Limited (Australia).